Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Amphotericin B deoxycholate (AmBd) has been a standard therapy for IFI but is associated with high adverse event and mortality rates. A retrospective review was undertaken to describe adverse events and clinical outcomes in adult patients with IFI treated with only AmBd as initial therapy.
Garbino
Jorge
J
Division of Infectious Diseases, University Hospitals of Geneva, Switzerland. jorge.garbino@hcuge.ch
Markham
Lydia
L
Matulionyte
Raimonda
R
Rives
Vincent
V
Lew
Daniel
D
D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003840:Deoxycholic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006760:Hospitalization; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies
D000935:Antifungal Agents; D004338:Drug Combinations; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination